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Digestive malignancies remain one of the leading causes of
cancer-related death worldwide despite the fact that increas-
ingclinicalandbiologicalknowledgehasemerged.Amongall
thenewlydiscoveredcancercases,colorectalcancer,stomach
cancer, liver cancer, and esophagus cancer rank in the front
and the mortality rate for them also tops the list. The poor
prognosisofdigestivetumorsispartiallyduetolatediagnosis,
delayed initiation of treatment, and unsatisfactory reaction
to cancer therapies. Many molecular markers have been dis-
c o v e r e df o re a r l yd i a g n o s i sa n db e t t e rt h e r a p e u t i co u t c o m e s
from which we do benefit a lot. However, diagnosis and
treatmentofalimentarycancersrequirefurtheroptimization.
We believe further study of novel molecular targets for early
detection and better treatment would be helpful to reduce
mortality rate and to improve the prognosis of malignant
diseases of digestive system.
In this current issue, we focus on recent advances in
the research of novel molecular targets which would help
revealthepossiblemechanismoftumorigenesis,progression,
metastasis, and recurrence of digestive malignancies. The
potential value of these molecular targets in cancer therapy
is also highlighted. We present 10 articles on novel molecular
targets in digestive system of which six articles discuss the
molecularmarkersinhepatocellularcarcinoma,threearticles
discuss the molecular makers in gastric carcinoma, and one
m a k e sac o m p r e h e n s i v er e v i e wo no n ea n t i c a n c e rt a r g e ti n
digestive system cancer therapy.
In the paper entitled “H-Ras oncogene expression and
angiogenesis in experimental liver cirrhosis,” by G. ¨ O. Elpek
et al. evaluated the relation between H-Ras expression and
angiogenesisinlivercirrhosiswhichcanprogresstolivercar-
cinoma.TheoncogeneH-Rasiselevatedinlivercirrhosisand
correlates significantly with angiogenesis.
“LEPREL1 expression in human hepatocellular carci-
noma and its suppressor role on cell proliferation”by J. Wang
et al. found that LEPREL1 was downregulated in hepatocel-
lular carcinoma (HCC) tissues both in mRNA and protein
levels, and the down-regulation was not associated with
conventional clinical parameters of HCC. LEPREL1 could
serveasapotentialtumorsuppressorgenebyinhibitingHCC
cell proliferation.
The research paper “Expression of potential cancer stem
cell marker ABCG2 is associated with malignant behaviors
of hepatocellular carcinoma” by G. Zhang et al. found that
ABCG2 could probably function as a liver cancer stem cell
marker because of its close relationship with tumorigenesis
and also because it could promote cell proliferation, drug
resistance, and metastasis. This molecule may represent an
attractive target for the innovation of cancer stem cell-
directed therapy for HCC.
In “Study of RNA interference targeting NET-1 combi-
nation with sorafenib for hepatocellular carcinoma therapy
in vitro and in vivo,” S. He et al. found that the interference
of NET-1 could enhance the anticancer effect of sorafenib.2 Gastroenterology Research and Practice
The interference of NET-1 could lead to impaired ability of
proliferation and migration and could induce apoptosis in
H C Cc e l ll i n e .N E T - 1m a yb eap r o m i s i n gm o l e c u l a rt a r g e t
to develop adjuvant therapy in combination with the only
effective targeted drug, sorafenib for HCC.
Another two articles talked about the function of mic-
roRNA in HCC. X.-Y. Huang et al. showed that miR-29 was
u p r e g u l a t e di nH C Ca n dc o r r e l a t e dw i t hp o o ro u t c o m e so f
HCC. It might function by promoting cell proliferation and
inhibiting cell apoptosis. The work by Z. Wang et al. clarified
the association of miR-499 and miR-34b/c polymorphisms
with susceptibility to HCC and got to the final conclusion
thatrs3746444wasnotassociatedwithsusceptibilitytoHCC
while rs4938723 was associated with increased HCC risk.
“Mastcellspositivetotryptaseandc-kitreceptorexpress-
ing cells correlates with angiogenesis in gastric cancer pa-
tients surgically treated” by M. Ammendola et al. studied
the angiogenesis in gastric cancer and found that MCTP and
c-kitR-EC correlated positively with microvascular density.
Drugs against c-kitR and tryptase could be promising agents
in antiangiogenic therapy.
“Significance of glutathione peroxidase 1 and caudal-re-
latedhomeodomaintranscriptionfactorinhumangastricad-
enocarcinoma,”J.J.Hanetal.demonstratedGPX1andCDX2
might participate in the carcinogenesis, differentiation, and
progression of gastric adenocarcinoma, and CDX2 might be
an independent prognostic factor.
“Indirect comparison showed survival benefit from adju-
vant chemoradiotherapy in completely resected gastric can-
c e rw i t hD 2l y m p h a d e n e c t o m y ”b yQ .Y a n ge ta l .c o n fi r m e d
the role of adjuvant chemoradiotherapy in D2-resected gas-
tric cancer patients with discussion of underlying molecular
m e c h a n i s mo ft h i sb e n e fi t .
Th er e v i e wa r t i c l e“ P P 2 A - m e d i a t e da n t i c a n c e rt h e r a p y ”
by W. Chen et al. made a general review of the tumor sup-
pressorPP2AbyfocusingonPP2Astructureandthepossible
mechanism of its participation in anticancer therapy.
In summary, this special issue presents several intriguing
achievements in the field of novel molecular targets in diges-
tive malignancies which we hope could be utilized in the fu-
ture for early diagnosis and treatment.
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